Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis

K Ghoreschi, A Balato, C Enerbäck, R Sabat - The Lancet, 2021 - thelancet.com
Psoriasis is a chronic inflammatory disease characterised by sharply demarcated
erythematous and scaly skin lesions accompanied by systemic manifestations. Classified by …

[HTML][HTML] Focus: skin: current developments in the immunology of psoriasis

F Grän, A Kerstan, E Serfling, M Goebeler… - The Yale journal of …, 2020 - ncbi.nlm.nih.gov
Psoriasis is a frequent inflammatory skin disease. Fundamental research on the
pathogenesis of psoriasis has substantially increased our understanding of skin …

Interleukin 17 is a chief orchestrator of immunity

M Veldhoen - Nature immunology, 2017 - nature.com
Increased understanding of the biology of interleukin 17 (IL-17) has revealed that this
cytokine is a central player in immunity at the sites most exposed to microorganisms …

Cytokines in uveitis

JE Weinstein, KL Pepple - Current opinion in ophthalmology, 2018 - journals.lww.com
Cytokines in uveitis : Current Opinion in Ophthalmology Cytokines in uveitis : Current Opinion in
Ophthalmology Log in or Register Subscribe to journalSubscribe Get new issue alertsGet alerts …

[HTML][HTML] The Role of IL-17 in Protection against Mucosal Candida Infections

BG Mengesha, HR Conti - Journal of fungi, 2017 - mdpi.com
Interleukin-17 (IL-17) is a proinflammatory cytokine produced by adaptive CD4+ T helper
cells and innate lymphocytes, such as γδ-T cells and TCRβ+“natural” Th17 cells. IL-17 …

Safety of guselkumab in patients with moderate‐to‐severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 …

K Reich, KA Papp, AW Armstrong… - British Journal of …, 2019 - academic.oup.com
Background Long‐term evaluation is required to confirm the safety profile of newer biologic
agents. Objectives To report on pooled safety data from the ongoing VOYAGE 1 …

Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry

B Lockshin, A Cronin, RW Harrison… - Dermatologic …, 2021 - Wiley Online Library
To compare drug survival of ixekizumab to other IL‐17 inhibitors (IL‐17i) and TNF inhibitors
(TNFi) among patients with psoriasis (PsO) in a real‐world setting. Participants included …

Histone modifications associated with biological drug response in moderate‐to‐severe psoriasis

MC Ovejero‐Benito, A Reolid… - Experimental …, 2018 - Wiley Online Library
Introduction Epigenetic factors play an important role in psoriasis onset and development.
Biological drugs are used to treat moderate‐to‐severe psoriasis patients resistant to …

Discovery of [cis-3-({(5R)-5-[(7-Fluoro-1,1-dimethyl-2,3-dihydro-1H-inden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridin-6(5H)-yl}carbonyl)cyclobutyl] …

M Kono, A Ochida, T Oda, T Imada… - Journal of Medicinal …, 2018 - ACS Publications
A series of tetrahydronaphthyridine derivatives as novel RORγt inverse agonists were
designed and synthesized. We reduced the lipophilicity of tetrahydroisoquinoline compound …

Targeting interleukin-23 in the treatment of noninfectious uveitis

KL Pepple, P Lin - Ophthalmology, 2018 - Elsevier
The interleukin (IL)-23/IL-17 axis plays a central role in the pathogenesis of immune-
mediated diseases such as psoriasis, psoriatic arthritis, Crohn's disease, and uveitis …